Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity
Anna J. Son, Emmanuel Rapp, Alex Wiezorek, Max G. Leung, Ronadip R. Banerjee, Thomas H. Leung
Anna J. Son, Emmanuel Rapp, Alex Wiezorek, Max G. Leung, Ronadip R. Banerjee, Thomas H. Leung
View: Text | PDF
Research Letter Endocrinology Metabolism

Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity

  • Text
  • PDF
Abstract

Authors

Anna J. Son, Emmanuel Rapp, Alex Wiezorek, Max G. Leung, Ronadip R. Banerjee, Thomas H. Leung

×

Figure 1

Cycling GLP-1 RA treatment induces therapeutic resistance and rebound obesity.

Options: View larger image (or click on image) Download as PowerPoint
Cycling GLP-1 RA treatment induces therapeutic resistance and rebound ob...
(A) Representative image of cycled and continuous semaglutide-treated (SEMA-treated) mice on day 120. (B) Body weight trajectories of Cohort 1 cycled (red, n = 6) and continuous (black, n = 7) mice. GTT, glucose tolerance testing; ITT, insulin tolerance testing. (C) Body weights of individual cycled mice 14 days after each cycle. (D) Fat, lean, and total mass by EchoMRI on day 83. (E) Mean adipocyte area in eWAT and iWAT, quantified from representative H&E-stained sections (F) (scale bar, 100 μm). (G) Plasma leptin levels in Cohort 1. (H) Body weight trajectories of Cohort 2 cycled (red, n = 6) and continuous (black, n = 7) mice over 95 days; green star, 1 missed treatment day. (I) Fat, lean, and total mass by EchoMRI on day 95. (J) Percentage weight change in cycled versus continuous mice across both cohorts. Unpaired 2-tailed Student’s t test. NS, not significant. *P < 0.05, **P < 0.01. Data presented as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts